ES2556211T3 - Agrupación de genes novedosa - Google Patents

Agrupación de genes novedosa Download PDF

Info

Publication number
ES2556211T3
ES2556211T3 ES09815612.8T ES09815612T ES2556211T3 ES 2556211 T3 ES2556211 T3 ES 2556211T3 ES 09815612 T ES09815612 T ES 09815612T ES 2556211 T3 ES2556211 T3 ES 2556211T3
Authority
ES
Spain
Prior art keywords
seq
nucleic acid
polypeptides
polyketide
module
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09815612.8T
Other languages
English (en)
Spanish (es)
Inventor
Wen Liu
Nan Jiang
Xudong Qu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Application granted granted Critical
Publication of ES2556211T3 publication Critical patent/ES2556211T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES09815612.8T 2008-09-24 2009-09-24 Agrupación de genes novedosa Active ES2556211T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200810200388 2008-09-24
CN200810200388 2008-09-24
PCT/CN2009/074178 WO2010034243A1 (en) 2008-09-24 2009-09-24 Novel gene cluster

Publications (1)

Publication Number Publication Date
ES2556211T3 true ES2556211T3 (es) 2016-01-14

Family

ID=42059282

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09815612.8T Active ES2556211T3 (es) 2008-09-24 2009-09-24 Agrupación de genes novedosa

Country Status (6)

Country Link
US (1) US8962329B2 (OSRAM)
EP (1) EP2342335B1 (OSRAM)
JP (1) JP5789190B2 (OSRAM)
CN (1) CN102224242B (OSRAM)
ES (1) ES2556211T3 (OSRAM)
WO (1) WO2010034243A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
CN107090476B (zh) 2010-12-20 2021-09-24 爱博利瓦有限公司 Sanglifehrin衍生物及其制备方法
US9428845B1 (en) * 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
CN104263738A (zh) * 2014-09-15 2015-01-07 武汉大学 Fas ii抑制剂abx的生物合成基因簇
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
EP3355930A4 (en) 2015-10-01 2019-03-06 Warp Drive Bio, Inc. METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
CN106916834B (zh) * 2015-12-24 2022-08-05 武汉合生科技有限公司 化合物的生物合成基因簇及其应用
EP4085933A3 (en) 2016-04-12 2023-01-11 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
WO2018081592A2 (en) 2016-10-28 2018-05-03 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
CN109943545B (zh) * 2019-03-29 2021-08-03 浙江大学 一种酰基转移酶结构域定向改造合成化合物的方法
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP3822348A1 (de) * 2019-11-12 2021-05-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Adaptersystem artifizieller nichtribosomaler peptidsynthetasen und polyketidsynthasen
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0725778T3 (da) * 1993-09-20 2001-12-17 Univ Leland Stanford Junior Rekombinant produktion af hidtil ukendte polyketider
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
EP0910633B1 (en) 1996-07-05 2009-12-09 Biotica Technology Limited Hybrid polyketide synthase I gene
US6265202B1 (en) * 1998-06-26 2001-07-24 Regents Of The University Of Minnesota DNA encoding methymycin and pikromycin
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
WO2001079520A1 (en) 2000-04-13 2001-10-25 Biotica Technology Limited Hybrid glycosylated products and their production and use
JP2005532809A (ja) 2002-07-16 2005-11-04 バイオチカ テクノロジー リミテッド ポリケチド、及び他の天然物の製造
GB0230217D0 (en) 2002-12-27 2003-02-05 Biotica Tech Ltd Borrelidin-producing polyketide synthase and its uses
GB0327721D0 (en) 2003-11-28 2003-12-31 Biotica Tech Ltd Polyketides and their synthesis
GB0327720D0 (en) 2003-11-28 2003-12-31 Biotica Tech Ltd Erythromycins and process for their preparation
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv

Also Published As

Publication number Publication date
CN102224242A (zh) 2011-10-19
US20110229941A1 (en) 2011-09-22
WO2010034243A1 (en) 2010-04-01
US8962329B2 (en) 2015-02-24
JP5789190B2 (ja) 2015-10-07
JP2012503478A (ja) 2012-02-09
EP2342335A4 (en) 2012-03-07
EP2342335B1 (en) 2015-09-16
EP2342335A1 (en) 2011-07-13
CN102224242B (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
ES2556211T3 (es) Agrupación de genes novedosa
AR083432A1 (es) Precursor de microarn y metodos para regular la expresion del gen objetivo
CO2019005085A2 (es) Composiciones y métodos para alterar la floración y arquitectura de planta para mejorar el potencial de rendimiento
AR091299A1 (es) Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para mejorar el rendimiento de las plantas
AR047166A1 (es) Promotor de metalotioneina de maiz
MX2018004265A (es) Metodo para producir plantas de genoma modificado a partir de protoplastos de planta a alta eficiencia.
AR081095A1 (es) Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estres abiotico y eficacia en el uso de nitrogeno
MX384304B (es) Polipéptidos y polinucleótidos aislados y métodos para su uso, para aumentar el rendimiento, la biomasa, el índice de crecimiento, el vigor, el contenido de aceite, la tolerancia al estrés abiótico de las plantas y la eficiencia en el uso de nitrógeno.
AR060523A1 (es) Moleculas de polinucleotidos aislados que corresponden a alelos mutantes y tipo salvaje del gen de maiz d9 y metodos para usarlas
AR040446A1 (es) Defensinas de plantas
ES2570962T3 (es) Producción incrementada de un producto diana vía estabilización del ARNm
AR087480A2 (es) Metodo para preparar una planta de cebada que posee una mutacion en el gen lox-1, composiciones de malta y metodos de produccion
RU2006132818A (ru) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
RU2017128034A (ru) Новый промотор и пути его применения
MX389590B (es) Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estres abiotico de las plantas y eficacia en el uso de nitrogeno.
AR050294A1 (es) Reduccion de zeina en semillas de maiz transgenico
CO6450629A2 (es) Gen de la proteína quinasa que se relaciona con snf1 de planta
IL275614B1 (en) Regeneration of genetically modified plants
Sykłowska-Baranek et al. Perfluorodecalin-supported system enhances taxane production in hairy root cultures of Taxus x media var. Hicksii carrying a taxadiene synthase transgene
AR065283A1 (es) Composiciones y metodos que utilizan arn de interferencia del gen tipo opr3 para el control de nematodos
AR065284A1 (es) Composiciones y metodos que utilizan arn de interferencia de tipo cdpk para el control de nematodos
JP2016513457A5 (OSRAM)
RU2015114955A (ru) Способ получения L-изолейцина с использованием бактерии семейства Enterobacteriaceae, в которой сверхэкспрессирован ген cycA
WO2017180180A3 (en) Plant promoter and 3' utr for transgene expression
CL2022001482A1 (es) Gen cca para la resistencia a los virus